Articles by William H. Crown - Pharmaceutical Executive


Articles by William H. Crown

Health Economics: Data Mining

Why No Stage of Drug Development and Marketing in the Brave New World of Biologics Can Be Without It
Sep 1, 2007

It's certainly not headline news that these are tough days for the pharmaceutical industry. More than $60 billion in revenue from blockbuster drugs will evaporate as these products go generic over the next five years, while the productivity of clinical development has hit a particularly rough patch. Even in the companies with relatively strong pipelines, many of the new treatments are biotech products acquired out of house. The expected authorization of biogenerics will squeeze profits only further.


Click here